Arno Therapeutics, Inc.
ARNI
$0.0001
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.47% | -17.75% | -21.31% | -23.90% | -28.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.13% | -31.17% | -34.15% | -36.42% | -39.55% |
| Operating Income | 22.13% | 31.17% | 34.15% | 36.42% | 39.55% |
| Income Before Tax | -364.27% | -398.56% | -344.97% | -248.09% | 85.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -364.27% | -398.56% | -344.97% | -248.09% | 85.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -364.27% | -398.56% | -344.97% | -248.09% | 85.63% |
| EBIT | 22.13% | 31.17% | 34.15% | 36.42% | 39.55% |
| EBITDA | 22.13% | 31.17% | 34.15% | 36.41% | 39.56% |
| EPS Basic | -196.89% | -263.83% | -308.23% | -247.94% | 89.29% |
| Normalized Basic EPS | -243.28% | -348.66% | -292.39% | -240.73% | 90.73% |
| EPS Diluted | -128.07% | -155.92% | -405.01% | -284.31% | 86.39% |
| Normalized Diluted EPS | -155.09% | -192.78% | -372.20% | -273.25% | 87.82% |
| Average Basic Shares Outstanding | 78.17% | 48.47% | 22.60% | 0.13% | 6.19% |
| Average Diluted Shares Outstanding | 69.05% | 33.97% | 5.45% | -13.88% | 0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |